Periadventitial application of rapamycin-loaded nanoparticles produces sustained inhibition of vascular restenosis

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Shi, Xudong ^a   Chen, Guojun ^b,c   Guo, Lian Wang ^a   Si, Yi ^a   Zhu, Men ^b,c   Pilla, Srikanth ^b   Liu, Bo ^a   Gong, Shaoqin ^b,c   Kent, K Craig ^a  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c Wisconsin Electric Machines and Power Electronics Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; NANOPARTICLE; POLYGLACTIN; RAPAMYCIN; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; CAROTID ARTERY; CAROTID ARTERY INJURY; CAROTID ARTERY RESTENOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; NONHUMAN; PERIADVENTITIAL DRUG DELIVERY; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RAT; RESTENOSIS; SMOOTH MUSCLE FIBER; TOXICITY TESTING; VASCULAR SMOOTH MUSCLE; ADVENTITIA; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; HYPERPLASIA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; SPRAGUE DAWLEY RAT;

ADVENTITIA; ANIMALS; CAROTID ARTERIES; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; HYPERPLASIA; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NANOPARTICLES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RIBOSOMAL PROTEIN S6 KINASES; SIROLIMUS;

EID: 84896801192     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089227     Document Type: Article

References (40)

1. Seedial SM, Ghosh S, Saunders RS, Suwanabol P, Shi X, et al. (2013) Local drug delivery to prevent restenosis. J Vasc Surg 57: 1403-1414.
2. Curcio A, Torella D, Indolfi C (2011) Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J 75: 1287-1296.
3. Acharya S, Sahoo SK (2011) PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 63: 170-183.
4. Lü J-M, Wang X, Marin-Muller C, Wang H, Lin PH, et al. (2009) Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 9: 325-341.
5. Martin-Banderas L, Durán-Lobato M, Muñoz-Rubio I, Alvarez-Fuentes J, Fernández-Arevalo M, et al. (2013) Functional PLGA NPs for oral drug delivery: recent strategies and developments. Mini Rev Med Chem 13: 58-69.
6. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161: 502-522.
7. Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, et al. (2010) In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine 6: 662-671.
8. Panyam J, Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55: 329-347. (Pubitemid 36297053)
9. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, et al. (2004) mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4E. Mol Cell Biol 24: 200-216. (Pubitemid 38010048)
10. Zohlnhofer D, Nuhrenberg TG, Neumann F-JJ, Richter T, May AE, et al. (2004) Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. Mol Pharmacol 65: 880-889. (Pubitemid 38420493)
11. Reddy MK, Vasir JK, Sahoo SK, Jain TK, Yallapu MM, et al. (2008) Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery. Circ Cardiovasc Interv 1: 209-216.
12. Daemen J, Kukreja N, van Twisk PH, Onuma Y, de Jaegere PP, et al. (2008) Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry. Am J Cardiol 101: 1105-1111.
13. Abizaid A Costa JR (2010) New drug-eluting stents: an overview on biodegradable and polymer-free next-generation stent systems. Circ Cardiovasc Interv 3: 384-393.
14. Virmani R, Farb A, Guagliumi G Kolodgie FD (2004) Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis 15: 313-318. (Pubitemid 39299245)
15. Siqueira DA, Abizaid AA, Costa J de R, Feres F, Mattos LA, et al. (2007) Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. Eur Heart J 28: 1304-1309. (Pubitemid 47355986)
16. Guzman LA, Labhasetwar V, Song C, Jang Y, Lincoff AM, et al. (1996) Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Circulation 94: 1441-1448. (Pubitemid 26307277)
17. Lutsiak MEC, Robinson DR, Coester C, Kwon GS, Samuel J (2002) Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 19: 1480-1487. (Pubitemid 35266552)
18. Clowes MM, Lynch CM, Miller a D, Miller DG, Osborne WR, et al. (1994) Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes. J Clin Invest 93: 644-651. (Pubitemid 24072805)
19. Kundi R, Hollenbeck ST, Yamanouchi D, Herman BC, Edlin R, et al. (2009) Arterial gene transfer of the TGF-beta signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF. Cardiovasc Res 84: 326-335.
20. Jhunjhunwala S, Raimondi G, Thomson a W, Little SR (2009) Delivery of rapamycin to dendritic cells using degradable microparticles. J Control Release 133: 191-197.
21. Brown MA, Zhang L, Levering VW, Wu J, Satterwhite LL, et al. (2010) Human Umbilical Cord Blood - Derived Endothelial Cells Reendothelialize Vein Grafts and Prevent Thrombosis. Arterioscler Thromb Vasc Biol 30: 2150-2155.
22. Tian W, Kuhlmann MT, Pelisek J, Scobioala S, Quang TH, et al. (2006) Paclitaxel delivered to adventitia attenuates neointima formation without compromising re-endothelialization after angioplasty in a porcine restenosis model. J Endovasc Ther 13: 616-629. (Pubitemid 44749193)
23. Tsai S, Hollenbeck ST, Ryer EJ, Edlin R, Yamanouchi D, et al. (2009) TGF-beta through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation. Am J Physiol Heart Circ Physiol 297: H540-H549.
24. Zhu W, Masaki T, Bae YH, Rathi R, Cheung AK, et al. (2006) Development of a sustained-release system for perivascular delivery of dipyridamole. J Biomed Mater Res B Appl Biomater 77: 135-143.
25. Kawatsu S, Oda K, Saiki Y, Tabata Y, Tabayashi K (2007) External application of rapamycin-eluting film at anastomotic sites inhibits neointimal hyperplasia in a canine model. Ann Thorac Surg 84: 560-567. (Pubitemid 47069159)
26. Makadia HK, Siegel SJ (2011) Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel) 3: 1377-1397.
27. Avgoustakis K, Beletsi a, Panagi Z, Klepetsanis P, Karydas a G, et al. (2002) PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 79: 123-135.
28. Ding M, Xie Y, Wagner RJ, Jin Y, Carrao AC, et al. (2011) Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex 1 and FoxO4. Arter Thromb Vasc Biol 31: 1403-1410.
29. Liuzzo JP, Ambrose JA Coppola JT (2005) Sirolimus- and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization. J Invasive Cardiol 17: 497-502.
30. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, et al. (2007) Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115: 1051-1058. (Pubitemid 46328299)
31. Rosner D, McCarthy N, Bennett M (2005) Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53. Cardiovasc Res 66: 601-610. (Pubitemid 40725772)
32. Yang J, Zeng Y, Zhang C, Chen Y-X, Yang Z, et al. (2013) The prevention of restenosis in vivo with a VEGF gene and paclitaxel co-eluting stent. Biomaterials 34: 1635-1643.
33. Jim J, Owens PL, Sanchez LA, Rubin BG (2012) Population-based analysis of inpatient vascular procedures and predicting future workload and implications for training. J Vasc Surg 55: 1394-1399.
34. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI (2011) Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 4: 1057-1066.
35. Si Y, Ren J, Wang P, Rateri DL, Daugherty A, et al. (2012) Protein kinase C-delta mediates adventitial cell migration through regulation of monocyte chemoattractant protein-1 expression in a rat angioplasty model. Arterioscler Thromb Vasc Biol 32: 943-954.
36. Siow RCM, Mallawaarachchi CM, Weissberg PL (2003) Migration of adventitial myofibroblasts following vascular balloon injury: Insights from in vivo gene transfer to rat carotid arteries. Cardiovasc Res 59: 212-221. (Pubitemid 36776387)
37. Cartiera MS, Johnson KM, Rajendran V, Caplan MJ SW, Cartiera MS, Johnson KM, Rajendran V, Caplan MJ, et al. (2009) The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 30: 2790-2798.
38. Pires NMM, van der Hoeven BL, de Vries MR, Havekes LM, van Vlijmen BJ, et al. (2005) Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff. Biomaterials 26: 5386-5394. (Pubitemid 40462353)
39. Chorny M, Fishbein I, Golomb G (2000) Drug delivery systems for the treatment of restenosis. Crit Rev Ther Drug Carrier Syst 17: 249-284. (Pubitemid 30421571)
40. Rajathurai T, Rizvi SI, Lin H, Angelini GD, Newby AC, Murphy GJ. (2010). Periadventitial rapamycin-eluting microbeads promote vein graft disease in long-term pig vein-into-artery interposition grafts. Circ Cardiovasc Interv. 3(2): 157-65.